Notice: Fall 2017 exams affected by natural disasters... More >

Expand/Collapse Close

ABIM knows that we have many physicians whose lives have been upended by recent natural disasters. If you live or work near an affected area, we understand that the weather may have impacted your ability to take your Fall 2017 exam as scheduled. We have developed a series of options to help you get through this process as smoothly as possible. If you have any questions, please call us at 1-800-441-ABIM (2246) or email request@abim.org.

American Board of Internal Medicine home page

MOC is a professionally determined standard that attests that an internist is staying current in knowledge and practice throughout his/her career.

Initial Certification indicates that physicians have met rigorous standards through intensive study, accredited training and evaluation and that they have the clinical judgment, skills and attitudes essential for the delivery of excellent patient care.

For more than 75 years, Certification by ABIM has stood for the highest standard in internal medicine and its 20 subspecialties.

Hematology Board Exam Committee

Mark M. Udden, MD, Chair

Dr. Udden, a board certified hematologist and internist, is Chief of Benign Hematology at Baylor College of Medicine (BCM) in Houston, Texas. He is Chief of Hematology at the Ben Taub General Hospital and Harris Health Smith Clinic. He is also an Attending Physician in the Baylor Clinic and consults at Saint Luke's-Catholic Health Initiatives-BCM Hospital and the Texas Children's Hospital Pavilion for Women. He has a special interest in sickle cell disease and hematology of pregnancy. He also co-chairs the second-year medical student course in hematology/oncology and has an active teaching role for resident and fellowship training at Baylor.

He has served at Baylor as Core Clerkship Director for Internal Medicine from 1990 to 2007 and Chairman of the Longitudinal Ambulatory Care Experience course from 1994 to 1999. He was an adjunct Assistant then Associate Professor in the Biomedical Engineering Department at Rice University from 1983 until 1992.

Dr. Udden is a member of the American Board of Internal Medicine Hematology Board and is Chair of the ABIM Hematology Board Exam Committee. He is a fellow of the American College of Physicians. At Baylor, he has received numerous teaching awards including the Barbara and Corbin J. Robertson, Jr. Presidential Award for Excellence in Education in 2008 and the Master Clinician Lifetime Award in 2013.

He received his undergraduate degree from the Massachusetts Institute of Technology and his medical degree from The University of Texas Southwestern Medical School. He completed his residency in internal medicine and a fellowship in hematology at Baylor College of Medicine.

As of January 2017, Dr. Udden reported the following external relationships:

Funding for clinical trial salary support, paid to Baylor College of Medicine, from the following company:

  • Sanofi, for a trial of leukine in dementia.

Kristie A. Blum, MD

Dr. Blum is an Associate Professor in the Division of Hematology and Section Head of the Lymphoma Program at The Ohio State University. She is board certified in Hematology and Medical Oncology with expertise and extensive experience in the clinical development of novel therapeutics for patients with aggressive B-cell non-Hodgkin (NHL) and Hodgkin's lymphoma (HL).

Dr. Blum has been a faculty member at The Ohio State University since 2003, as an Associate Professor from 2010 to 2015 and as an Assistant Professor from 2003 to 2010.

Dr. Blum was the Associate Director of the Hematology/Oncology Fellowship Program from 2005-2008 and the Director of the Hematology/Oncology Fellowship from 2008-2013. Stepping down from her fellowship role, she led The Ohio State University Lymphoma Clinical and Research Programs in 2013. Dr. Blum also serves on the American Board of Internal Medicine Hematology Board Exam Committee, the Lymphoma Research Foundation Scientific Advisory Board, the Alliance Co-Operative Group Lymphoma Committee, the American Society of Hematology Clinical Research Mentoring Program, and the National Comprehensive Cancer Network Hodgkin's Lymphoma Panel. She has directed and chaired the first Lymphoma Research Foundation Clinical Research Mentoring Program.

Dr. Blum has experience in the design, conduct and publication of phase I-II trials, with focused interest in drug development in lymphomas. She has been involved in several high-impact pharmaceutical trials including trials with lenalidomide, ibrutinib, brentuximab and idelalisib that have led to FDA approvals of several of these agents.

Dr. Blum earned her medical degree at the University of Miami. She completed internal medicine residency from 1997 to 2000 at University of Virginia, her hematology/oncology fellowship training at Vanderbilt University from 2000 to 2001 and Washington University in St. Louis from 2001 to 2003.

As of January 2017, Dr. Blum reported the following external relationships:

Funding for clinical trial expenses and staff, paid to The Ohio State University, from the following companies:

  • Cephalon, for a Phase ½ study of gemcitabine and bendamustine in patients with Hodgkin lymphoma.
  • MorphoSys, for a trial of anti-CD19 antibody in relapsed non-Hodgkin lymphoma patients.

Funding for clinical trial expenses, staff and salary support, paid to The Ohio State University, from the following companies:

  • Celgene, for trials of lenalidomide in patients with non-Hodgkin lymphoma and Hodgkin lymphoma.
  • Morphosys, for a trial of anti-CD19 antibody in patients with relapsed non-Hodgkin lymphoma.
  • Seattle Genetics, for trials of brentuximab in relapsed and upfront Hodkin lymphoma, and of SGN-40 in non-Hodgkin lymphoma.
  • Pharmacyclics, for trials of ibrutinib and R-bendamustine in relapsed lymphoma.
  • Novartis, for trials of MCL-1 inhibitor in relapsed lymphoma.

Dr. Blum serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Alliance for Clinical Trials in Oncology, Alliance Lymphoma Committee, Cadre Member, receiving reimbursement for travel expenses.
  • Lymphoma Research Foundation, Scientific Advisory Board; LRF Clinical Research Mentoring Program, Chair, receiving reimbursement for travel expenses.

Morie A. Gertz, MD

Dr. Gertz is the Roland Seidler Jr. Professor of the Art of Medicine and Chair of the Department of Medicine at the Mayo Clinic. He is board certified in Internal Medicine, Hematology and Medical Oncology.

Previously, Dr. Gertz served as Treasurer for the International Myeloma Society and as President of Mayo Staff Officers and Councilors. He was the Chair of the Mayo Personnel Committee. He currently serves on the American Society of Hematology Training Program Committee and the American Board of Internal Medicine Hematology Board Exam Committee.

He has been recognized with the 2014 Jan Waldenström Medal for Medical and Scientific Acheivements in Waldenström's Macroglobulinemia and is a Mayo Distinguished Clinician. He has been recognized for his contributions in amyloidosis and Waldenström's macroglobulinemia. He has authored more than 500 peer-reviewed publications in the field and is a frequently invited speaker nationally.

Dr. Gertz is a master of the American College of Physicians. His undergraduate degree was awarded with highest distinction from Northwestern University, graduating Phi Beta Kappa. He received his medical degree cum laude from Loyola Medical School and was elected to Alpha Omega Alpha, the medical honor society. He completed a three-year medical residency at Rush Presbyterian St. Luke's Hospital in Chicago and was voted Resident of the Year for two of those years.

As of January 2017, Dr. Gertz reported the following external relationships:

Preclinical research, with funding for staff provided to the Mayo Clinic, from the following company:

  • Annexon Biosciences, for patient sera for antibody testing.

Funding for clinical trial expenses and staff, from the following companies:

  • Alnylam, for a trial of imRNA for familial amyloidosis, providing funding for staff, paid to Mayo Clinic.
  • Isis Pharmaceuticals, for a trial of IRNA for familial amyloidosis, providing funding for staff and expenses.
  • Millennium for a trial of bortezomib for amyloidosis AL, providing funding for staff, paid to Mayo Clinic.
  • Pfizer Pharmaceuticals, for a trial of tafamidis for cardiac amyloidosis, providing funding for staff, paid to Mayo Clinic.

Attendance at investigators' meetings, with compensation as listed from the following companies:

  • Millennium, to discuss a strategic planning model, receiving reimbursement for travel expenses and honoraria.
  • Novartis, for sales force education, receiving reimbursement for travel expenses and honoraria.

Service on data and safety monitoring boards for the following company, with honoraria:

  • AbbVie, for a Phase III trial of venetoclax.

Service on research-related expert panel or advisory board for the following company, with compensation as listed:

  • Celgene, to advise on medical content of lectures sponsored by the company, receiving reimbursement for travel expenses and honoraria.

Industry-supported continuing medical education supported by the following, with compensation as listed:

  • Onyx, receiving reimbursement for travel expenses and honoraria.

Teaching in industry-sponsored satellite symposia with funding from the following company, with compensation as

  • Research to Practice, a medical education company that receives support from pharmaceutical companies, receiving reimbursement for travel expenses and honoraria.

Work as an author or editor for following company, with compensation as listed:

  • BMJ Point of Care, receiving compensation for creating online content.

Dr. Gertz serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Society of Hematology, Training Committee, receiving reimbursement for travel expenses.
  • Amyloidosis Support Network, receiving reimbursement for travel and other expenses associated with providing lectures to patients.
  • International Waldenstroms Macroglobulinemia Foundation receiving reimbursement for travel and other expenses associated with providing lectures to patients.

Cindy A. Leissinger, MD

Dr. Leissinger is Professor of Medicine and Clinical Professor of Pediatrics and Pathology at Tulane University in New Orleans, Louisiana, and is Chief of the Hematology/Oncology Division there. She became Director of the Louisiana Comprehensive Hemophilia Care Center (now the Louisiana Center for Bleeding and Clotting Disorders) in 1992, and has remained in that position ever since. She is board certified in Internal Medicine and Hematology.

In addition to caring for patients with bleeding and clotting disorders, Dr. Leissinger oversees an active research program. She participates in several clinical research groups, and has been an active investigator for many research studies related to bleeding disorders, with a particular interest in Factor VIII inhibitor development and management.

Dr. Leissinger is a member of the American Board of Internal Medicine Hematology Board Exam Committee. Additionally, she is actively involved in the American Society of Hematology, the International Society on Thrombosis and Haemostasis, and the Hemostasis and Thrombosis Research Society.

Dr. Leissinger received her medical degree from Tulane University School of Medicine. She completed a residency in internal medicine at Tulane, a research fellowship in hematology at The National Institutes of Health in Bethesda, Maryland, and a clinical fellowship in hematology and medical oncology at Tulane.

As of January 2017, Dr. Leissinger reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Tulane University, from the following companies:

  • CSL Behring, for a study of a new FVIII product.
  • Roche, for a study of a new Factor VIII mimetic protein.

Dr. Leissinger serves in a significant role with the following organization:

  • Hemostasis and Thrombosis Research Society, President-Elect, receiving no compensation.

Michael L. Linenberger, MD

Dr. Linenberger, who is board certified in Internal Medicine and Hematology, is the Robert and Phyllis Henigson Endowed Professor of Hematology and serves as the Program Director of the Hematology/Oncology Fellowship Program at the University of Washington (UW) School of Medicine. In his role as Medical Director of Cellular Therapy and Apheresis at the Seattle Cancer Care Alliance (SCCA), Dr. Linenberger supports the activities of the Cell Processing Core of the Fred Hutchinson Cancer Research Center, which provides critical instrumentation and technical expertise for the procurement, characterization and processing of all clinical cellular components necessary for the treatment of patients and for correlative research studies. These activities support the investigational protocols that utilize the Cellular Processing Facility (a GMP production laboratory) and a research specimen repository. At the SCCA Hematology Clinic, as well as the inpatient Hematology Consult service at UW Medical Center, Dr. Linenberger cares for patients who have disorders ranging from anemia and sickle cell disease to bleeding and thrombotic disorders to leukemia, lymphoma and myeloproliferative disorders.

Dr. Linenberger serves as a member of the American Board of Internal Medicine's Hematology Board Exam Committee. He is the local Principal Investigator on a multicenter study of hematopoietic stem cell donor safety and quality of life, sponsored by the Center for International Blood and Marrow Transplant Research. Dr. Linenberger has participated in national standards committees, applications and governance committees, and working groups of AABB and ASFA, which established policies for cellular therapy, apheresis and donor safety. He has directed and participated in research protocols studying stem cell donor safety and adverse events related to stem cell infusions. Dr. Linenberger's other interests include optimization of methods for stem cell procurement, therapeutic apheresis approaches for post-transplant graft-versus-host disease, and cellular therapy applications relevant to hematopoietic stem cell transplantation. In 2005, he received the Fred Hutchinson Cancer Research Center Clinical Research Division's Ali Johany Prize for excellence in patient care.

Dr. Linenberger received his medical degree at the University of Kansas. He completed internal medicine residency training at Rhode Island Hospital (Brown University) and a hematology fellowship at the University of Washington.

As of January 2017, Dr. Linenberger reported the external relationships:

Dr. Linenberger serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American Society for Apheresis, Board of Directors, receiving reimbursement for travel expenses.
  • American Society of Hematology, Continuing Medical Education Accreditation Subcommittee, Chair, receiving reimbursement for travel expenses.
  • American Society of Hematology, Committee on Educational Affairs, Chair, receiving reimbursement for travel

Robert T. Means Jr., MD

Dr. Means, a board certified internist and hematologist, is Dean and Professor of Internal Medicine at the James H. Quillen College of Medicine, East Tennessee State University in Johnson City, Tennessee.

Before coming to Quillen, he was Executive Dean of the University of Kentucky College of Medicine. Other positions Dr. Means held at Kentucky included Senior Associate Chair of Internal Medicine, Interim Director of the Markey Cancer Center and Chief of the Medical Service at the Lexington VA Medical Center. He served as Director of the Hematology Oncology Division at the Medical University of South Carolina, and was on faculty at the University of Cincinnati and Vanderbilt.

Dr. Means is a member of the American Board of Internal Medicine Hematology Board Exam Committee. He is past President of the Southern Society for Clinical Investigation and a Fellow of the American College of Physicians. He is also an Associate Editor of the Journal of Investigative Medicine, and serves on editorial boards for the American Journal of the Medical Sciences, Blood Research, and International Journal of Hematology. He is on the Medical & Scientific Advisory Board of the Iron Disorders Institute.

Dr. Means received his bachelor's degree in biochemistry from Rice University in Houston, Texas. He earned his medical degree at Vanderbilt University in Nashville, Tennessee. He trained in internal medicine at Baylor College of Medicine Affiliated Hospitals in Houston, Texas, before returning to Vanderbilt for a fellowship in hematology.

As of January 2017, Dr. Means reported the following external relationships:

Service on data and safety monitoring boards for the following company, with compensation for honoraria provided to East Tennessee State University Quillen College of Medicine:

  • Sanofi, effect of innate immunity modification by cytokines on Alzheimer's disease

Consulting on design of clinical trial for the following company, with compensation for honoraria provided to East Tennessee State University Quillen College of Medicine:

  • Xenon, trial design for hepcidin-directed therapeutics.

Work as an author or editor for following companies, with compensation as listed:

  • Lippincott Williams Wilkins/Wolters Kluwer, receiving royalties for the textbook, Wintrobe's Clinical Hematology, 12th and 13th editions.

Dr. Means serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Southern Society for Clinical Investigation, Executive Advisory Committee, compensation for lodging at annual retreat provided directly to hotel.
  • Iron Disorders Institute, Member of the Medical & Scientific Advisory Board, without compensation.

Anne T. Neff, MD

Dr. Neff is currently a staff physician in Benign Hematology at the Cleveland Clinic Hospitals' Department of Hematology/Medical Oncology. She is board certified in Internal Medicine, Hematology, Blood Banking and Transfusion Medicine.

Previously, Dr. Neff was a Professor of Medicine, Pathology, Microbiology and Immunology at Vanderbilt University. There she also served as Director of the Hemostasis & Thrombosis Clinic, Director of Transfusion Medicine and was the founding Director of the stem cell collection program.

Dr. Neff has served on national committees for the American Association of Blood Banks including Chair of the Scientific Section of the Annual Program Planning committee, Standards Committee for Blood Banks and Transfusion Services, and Standards for Cellular Therapy Products. She has served on the American Society of Hematology's (ASH) Transfusion Scientific Committee and as a speaker at the Highlights of ASH programs in 2014. She was elected to serve on the Board of Directors for the Hemophilia and Thrombosis Research Society from 2008 to 2011. Additionally, Dr. Neff is a member of the American Board of Internal Medicine Hematology Board Exam Committee.

Dr. Neff earned her bachelor's degree in psychology at the University of Missouri-Columbia, where she also graduated with her medical degree and trained in internal medicine. She did her fellowship training in hematology at Vanderbilt University.

As of January 2017, Dr. Neff reported the following external relationships:

Funding for clinical trial staff, paid to the Cleveland Clinic Foundation, from the following companies:

  • Shire Pharmaceuticals, for a registry of patients with acquired hemophilia who receives recombinant porcine factor VIII.

Service on data and safety monitoring boards for the following company, with compensation as listed:

  • Pfizer, for a recombinant FXa Phase I trial in bleeding disorder patients, receiving an hourly rate for work performed.
  • American Thrombosis and Hemostasis Network, for staff and salary support from, paid to Cleveland Clinic Foundation, to collate data for epidemiologic studies.

David L. Porter, MD

Dr. Porter, a board certified hematologist, is the Jodi Fisher Horowitz Professor of Leukemia Care Excellence at the Perelman School of Medicine and Abramson Cancer Center, and Director of the Blood and Marrow Transplantation and Cellular Therapeutics program at the Hospital of the University of Pennsylvania.

Dr. Porter is a member of the American Board of Internal Medicine Hematology Board Exam Committee. Additionally, he chairs or serves on numerous local, national and international committees focused on hematologic malignancies and hematopoietic stem cell transplantation. He is a member of the Board of Directors of the National Marrow Donor Program. He is a member of the American Society of Hematology, the American Society of Clinical Oncology and the American Society for Blood and Marrow Transplantation.

Dr. Porter has authored more than 140 research articles and book chapters, is an Associate Editor for the American Journal of Hematology and has served as a manuscript reviewer for numerous medical journals, including Blood, Annals of Internal Medicine and The New England Journal of Medicine. He is annually recognized as a “Top Doc” in Philadelphia Magazine and by Castle Connolly and in 2007 was the recipient of the Leukemia & Lymphoma Society Service to Mankind Award, which is bestowed for “dedicated service to the highest standards of the medical profession, his humanistic approach to patient care and his tireless efforts in researching cures for blood cancers”.

Dr. Porter has expertise in the care of patients with hematologic malignancies including acute and chronic leukemia and in all aspects of autologous and allogeneic stem cell transplantation (SCT) and leads numerous local and national research activities. He is an accomplished clinical investigator and has published extensively in the field of stem cell transplantation and hematologic malignancies. His principal research interests are in development of novel methods of cellular therapy, stem cell transplantation and allogeneic adoptive immunotherapy.

Dr. Porter is a graduate of the University of Rochester and earned a medical degree at Brown University. He completed internship and residency at Boston University Hospital, and fellowship training at Brigham and Women's Hospital and Harvard Medical School in Boston.

As of January 2017, Dr. Porter reported the following external relationships:

Funding for clinical trial expenses and staff, paid to the University of Pennsylvania, from the following company:

  • Alexion, to study the use of complement inhibitor to treat graft versus host disease.

Funding for clinical trial expenses, staff, and salary support, paid to the University of Pennsylvania, from the following company:

  • Novartis, for a study of the use of CTL019 cells to treat chronic lymphocytic leukemia, acute lymphocytic leukemia, non-Hodgkin lymphoma and myeloma.

Service on data and safety monitoring boards for the following companies, with compensation as listed:

  • Center for International Blood and Marrow Research, serving as Chair of the Research in Clinical Investigation Bone Marrow Transplant data and safety monitoring board, overseeing several sponsored clinical trials, receiving honoraria.

Work as an author or editor for following companies, with compensation as listed:

  • Wiley, receiving compensation as Associate Editor of the American Journal of Hematology.

Dr. Porter holds a healthcare-related patent for CTL019 cells to treat leukemia and lymphoma, with income from Novartis paid to the University of Pennsylvania.

  • Blood and Marrow Transparent Clinical Trials Network, for project expenses, staff and salary support for numerous clinical trials, paid to the University of Pennsylvania.

Dr. Porter serves in a significant role with the following organization, receiving reimbursement or compensation as listed:

  • National Marrow Donor Program, Board of Directors, receiving reimbursement for travel expenses.

David P. Steensma, MD

Dr. Steensma is a faculty member at Harvard Medical School and Director of the Myelodysplastic Syndromes Clinical Program at the Dana-Farber Cancer Institute in Boston, Massachusetts. He is board certified in Internal Medicine, Hematology and Medical Oncology.

Following completion of his formal training, Dr. Steensma spent several years as a visiting research scholar in the Molecular Haematology Unit of the Weatherall Institute of Molecular Medicine, University of Oxford, England, investigating the molecular genetics of myelodysplastic syndromes. He has published more than 250 peer-reviewed papers, and served as editor for several American Society of Hematology (ASH) publications, Education Chair for the ASH Annual Meeting, and section editor for the Journal of Clinical Oncology. He is a member of the American Board of Internal Medicine Hematology Board Exam Committee.

Originally from New Jersey, Dr. Steensma received his medical degree from the University of Chicago’s Pritzker School of Medicine following undergraduate work in physics and astronomy at Calvin College in Michigan. He completed internal medicine residency and a combined hematology-oncology fellowship at Mayo Clinic in Rochester, Minnesota.

As of January 2017, Dr. Steensma reported the following external relationships:

Preclinical research, with funding for salary support provided to Dana-Farber Cancer Institute, from the following companies:

  • Aplastic Anemia and MDS International Foundation, receiving funding for staff and expenses for research on molecular mechanisms of myelodysplastic syndromes in Vietnam-era veterans.
  • The V Foundation for Cancer Research, receiving salary support for a study of molecular mechanisms of myeloproliferative neoplasms.

Funding for clinical trial expenses and staff, paid to Dana-Farber Cancer Institute, from the following companies:

  • Celgene, for a myelodysplastic syndrome/acute myeloid leukemia national registry.
  • Genentech, for a trial of atezolizumab in myelodysplastic syndrome.
  • Janssen, for a trial of imetelstat in myelodysplastic syndrome.
  • Kura Oncology, for a trial of tipifamib in lower-risk myelodysplastic syndrome.
  • Syros Pharmaceuticals, for a trial of tamibarotene in myelodysplastic syndrome.

Service on data and safety monitoring boards for the following companies, receiving honoraria:

  • Janssen, for a CD123 antibody trial.
  • Onconova, for an international rigosertib trial in myelodysplastic syndrome.

Work as an author or editor for following companies, with compensation as listed:

  • American Society of Hematology, receiving compensation as associate editor of ASH Clinical News.
  • UpToDate, receiving compensation for co-authorship of sections on chronic myelomonocytic leukemia and erythropoiesis-stimulating agents in cancer.

Dr. Steensma holds a healthcare-related patent for erythropoiesis-stimulating agents dosing algorithm in renal failure, owned by Mayo Medical Laboratories, receiving no current income.

Dr. Steensma serves as Chair of Patient Education Council for Aplastic Anemia & MDS International Foundation.

Dr. Steensma serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • Aplastic Anemia & MDS International Foundation, Chair of Patient Education Council, without compensation.

Dr. Steensma serves in a significant role with the following organization, receiving reimbursement or compensation as listed:

  • Edward P. Evans Foundation/MDS Clinical Research Consortium, receiving salary support as a site principal investigator on one of six Consortium sites.

Dr. Steensma also reported serving as a member of the American Society of Hematology Committee on Educational Affairs.